HEPATOCELLULAR CARCINOMA (HCC)

This study is testing a combination of an immunotherapy drug (tislelizumab) and a traditional Chinese herbal granule (Huaier) as the first treatment for advanced liver cancer that cannot be removed by surgery. It will involve 94 patients to see if this combo can shrink tumors, co…

This study is testing a new drug called pumitamig, both by itself and combined with an existing drug (ipilimumab), for people with advanced liver cancer that cannot be removed by surgery. The main goals are to see if these treatments are safe and if they can shrink tumors. It is …

This study compares two different radiation-based treatment strategies for people with large, advanced liver cancer that cannot be removed by surgery. Participants will receive either a combination of two procedures (TACE followed by SBRT) or a single radiation procedure (Y90 SIR…

This study is testing whether a specific injection can help protect the liver from damage during and after surgery to remove part of the liver for cancer. Researchers will compare two groups: one receives the liver-protecting injection before surgery and a combination of injectio…

This study is testing HLX13, a biosimilar (highly similar copy) of the cancer drug ipilimumab, in people with advanced liver cancer that cannot be removed by surgery. The main goal is to see if HLX13 behaves similarly in the body to the original drug and is safe. Researchers will…

This is the first human study of an experimental antibody drug called CBA-1205 for people with advanced solid tumors that haven't responded to standard treatments. The trial will test the drug's safety and find the right dose in 66 adults and children with various cancers includi…

This study is testing whether delivering a specific chemotherapy regimen directly into the liver's artery after surgery can help prevent liver cancer from coming back in patients at high risk of recurrence. It will enroll about 30 adults who have recently had successful surgery t…

This study is testing whether adding the experimental drug ABSK-011 to standard supportive care helps control advanced liver cancer better than supportive care alone. It's for patients whose cancer has worsened despite previous treatments and who have a specific biomarker called …

This study is testing whether adding a capsule called Icaritin to a specific type of chemotherapy can help prevent liver cancer from returning after surgery. It is for patients whose cancer has a high risk of coming back. Researchers will check if this combination is safe and eff…

This study compares two methods of delivering chemotherapy directly to liver tumors in patients with advanced liver cancer who have previously had a TIPS shunt placed to manage complications of liver disease. Researchers want to see if using special drug-coated beads (DEB-TACE) h…

This study is observing whether a procedure called TIPS, which creates a shunt to relieve pressure in the liver, helps patients with advanced liver cancer. The goal is to see if this procedure allows patients to better tolerate and potentially get more benefit from their standard…

This study is testing a two-drug combination (sintilimab and a bevacizumab biosimilar) given after surgery to see if it can prevent liver cancer from coming back. It focuses on a dangerous situation where the liver tumor has ruptured, which greatly increases the risk of the cance…

This study is testing a new combination of three drugs (AK104, AK112, and TT-00420) for people with advanced liver cancer that cannot be treated with surgery. The main goal is to see how well the combination shrinks tumors and controls the disease. It will involve about 100 parti…

This study is testing a new combination of drugs for patients with advanced liver cancer whose initial immunotherapy treatment has stopped working. It aims to see if adding a specific chemotherapy regimen to the original drugs can better control the cancer and extend life. The tr…

This study is testing whether a new DNA vaccine called NWRD06 can help prevent liver cancer from coming back after patients have had it surgically removed. The vaccine targets a specific protein found on some liver cancer cells. About 30 patients who recently had successful surge…

This early-stage study is testing a new drug called Sapu003 in people with advanced cancers that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose, and to see how the body processes the drug. The study includes 27 adults with…

This study is for people who had surgery for liver cancer but are at high risk of it coming back. It compares two different follow-up treatments to see which is better at keeping the cancer away. One group gets a combination of targeted radiation and an immunotherapy drug. The ot…

This study is developing a computer-based planning tool to make a common liver cancer treatment more precise. The treatment involves injecting tiny radioactive beads into the liver's blood vessels to attack tumors. Researchers will use patient scans to create digital models, hopi…

This study is testing whether a radiation treatment for large liver tumors can be safely completed in a single day instead of over multiple visits. Researchers will enroll 138 patients with specific tumor characteristics to see if this faster approach works well. The goal is to c…

This is a very early-stage study to test the safety of a new drug called CREPT-618 in adults with advanced liver cancer that has stopped responding to standard treatments. The main goal is to find a safe dose by giving small groups of patients increasing amounts of the drug and w…

This early-stage trial is testing a new oral medication called ST-01156 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early s…

This study is testing a new drug called XL092, both by itself and in combination with other immunotherapy drugs, for people with advanced solid tumors that cannot be removed by surgery. The main goals are to find safe doses and see if the treatments can shrink tumors or slow thei…

This study is testing a combination of two drugs (apatinib and camrelizumab) plus a procedure called TACE as a treatment given before surgery for liver cancer. The goal is to shrink the tumor first, making it easier to remove completely during surgery and hopefully lowering the c…

This study is testing a combination treatment to prevent liver cancer from coming back after surgery in patients at high risk of recurrence. It combines a targeted liver procedure (TACE) with an oral medication (icaritin). The main goal is to see if this approach helps patients s…

This study aims to develop a simple blood test to detect six different gastrointestinal cancers earlier than current methods. Researchers will analyze blood samples from 1,000 people, including those with cancer and healthy controls, to find tiny genetic signals that indicate can…

This study is testing a new imaging method called 'multiplexed PET' to see if it can better find and map out two types of cancer: liver cancer (HCC) and certain digestive tract tumors (GEP-NETs). Instead of needing two separate scans, this method uses two different radioactive tr…

This study aims to find the best way to detect liver cancer early in people with advanced liver disease (cirrhosis). Researchers will follow 600 adults with cirrhosis, comparing two scanning methods—ultrasound and a shorter MRI—to see which is more effective at spotting cancer. T…

This study is testing a new imaging agent called 89Zr-TLX250 to see if it can help doctors better detect and locate three specific types of cancer using a PET-CT scan. The trial will involve 60 adults with liver cancer, bile duct cancer, or certain neuroendocrine tumors. The main…

This study aims to develop a more accurate blood test to detect liver cancer (hepatocellular carcinoma) at its earliest stages. It will enroll 600 people with a confirmed liver cancer diagnosis to test a new method that looks for specific genetic signals in the blood. Finding can…

This study is testing a new computer system that uses artificial intelligence (AI) to analyze CT scans. The goal is to predict before surgery whether a patient's liver cancer has started to invade small blood vessels, a key sign of aggressive disease. If successful, this tool cou…

This study is testing a new diagnostic platform that uses artificial intelligence to analyze small pieces of a patient's tumor. The goal is to predict whether a patient's cancer will respond to immunotherapy drugs before they start treatment. Researchers will compare the AI's pre…

This study is testing whether regular screening can help prevent deaths from liver cancer in people with cirrhosis (scarred liver). About 600 patients in one region of Denmark will get liver ultrasounds and a blood test every six months to try to catch cancer early. Researchers w…

This study is testing whether simple blood tests can predict how well a radiation treatment (Y90) works for liver cancer. Researchers will collect blood samples from 12 patients before and after treatment to look for cancer signals. The goal is to see if these blood signals can t…

This study aims to learn if simple blood tests can predict or monitor how well a standard liver cancer treatment works. Researchers will observe 15 adult patients with liver cancer who are scheduled to receive a procedure called TACE. They will collect blood samples before and af…

This study aims to understand if a patient's emotional state affects how well they respond to a specific combination treatment for advanced liver cancer. Researchers will observe 90 patients receiving standard therapy, grouping them by their mood scores, and track their health ou…